A novel way of analyzing mucus binding that could lead to better drug development has been developed by researchers and reported in ACS’ Biomacromolecules.
Mucus is a water-based substance comprised largely of mucins, large proteins with sugars on them that provide its signature gooey-ness. It serves as a protective layer in the lungs, stomach and other organs. Diseases, such as cystic fibrosis and asthma, result in an overproduction of mucus, so a better understanding of how various substances stick to the slimy material could help researchers develop better treatments. Previous studies have been limited in their scope or have relied on indirect measurements. That’s why Jacob Witten, Tahoura Samad and Katharina Ribbeck developed a new technique to measure an array of molecules and how they bind mucin and other biopolymers in mucus.
‘New strategy could facilitate new advances in treating diseases namely cystic fibrosis and asthma that are associated with mucus overproduction.’
The researchers’ new strategy was based on equilibrium dialysis. Mucin or another mucus component was on one side of a dialysis membrane. Molecules that bound to mucus components concentrated on one side of the membrane, whereas molecules that didn’t bind were at the same concentration on both sides. Their new workflow allowed them to analyze the binding of thousands of small molecules to mucus components. With the method, the researchers found a previously unknown pattern, or motif, associated with mucin binding.